Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080143 | 0.90 | CYP1A2 (0.46) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL4693129 | 0.75 | CYP1A2 (0.54) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL4690968 | 0.74 | KDM4E (0.55) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL901495 | 0.73 | L3MBTL1 (0.54) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL20871233 | 0.72 | CA2 (0.61) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL5464541 | 0.71 | ALDH1A1 (0.49) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL4093769 | 0.70 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL6540100 | 0.70 | L3MBTL1 (0.59) | L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL2290451 | 0.70 | CYP3A4 (0.56) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL11489148 | 0.69 | KDM4E (0.55) | L3MBTL1CYP1A2CYP3A4CYP2D6BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | claimed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | claimed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | claimed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | claimed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | L3MBTL1 4595/4885CYP1A2 624/4885CYP3A4 425/4885 |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | L3MBTL1 4702/4885CYP1A2 318/4885CYP3A4 193/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | L3MBTL1 4397/4885CYP1A2 782/4885CYP3A4 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.